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We analysed the molecular genetic profiles of breast cancer samples before and after neoadjuvant chemotherapy with combination
doxorubicin and cyclophosphamide (AC). DNA was obtained from microdissected frozen breast core biopsies from 44 patients
before chemotherapy. Additional samples were obtained before the second course of chemotherapy (D21) and after the
completion of the treatment (surgical specimens) in 17 and 21 patients, respectively. Microarray-based comparative genome
hybridisation was performed using a platform containing B5800 bacterial artificial chromosome clones (genome-wide resolution:
0.9Mb). Analysis of the 44 pretreatment biopsies revealed that losses of 4p, 4q, 5q, 12q13.11–12q13.12, 17p11.2 and 17q11.2; and
gains of 1p, 2p, 7q, 9p, 11q, 19p and 19q were significantly associated with oestrogen receptor negativity. 16q21–q22.1 losses were
associated with lobular and 8q24 gains with ductal types. Losses of 5q33.3–q4 and 18p11.31 and gains of 6p25.1–p25.2 and Xp11.4
were associated with HER2 amplification. No correlations between DNA copy number changes and clinical response to AC were
found. Microarray-based comparative genome hybridisation analysis of matched pretreatment and D21 biopsies failed to identify
statistically significant differences, whereas a comparison between matched pretreatment and surgical samples revealed a statistically
significant acquired copy number gain on 11p15.2–11p15.5. The modest chemotherapy-driven genomic changes, despite profound
loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages.
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Breast cancer is a heterogeneous disease comprising tumours with
remarkably distinct clinical behaviour (Simpson et al, 2005). In the
last 20 years, a multitude of prognostic and predictive markers
have been tested, however only oestrogen receptor, progesterone
receptor and HER2 are currently used to tailor the therapy of
breast cancer patients (Goldhirsch et al, 2005). The use of
expression arrays to derive molecular profiles that are predictive
of clinical outcome has received great attention in the last 5 years
(van’t Veer et al, 2005; Reis-Filho et al, 2006b), especially in the
neoadjuvant setting (Davidson and Morrow, 2005). Predictive
signatures for different neoadjuvant chemotherapy regimens have
been reported by some investigators but with less success by others
(Chang et al, 2003; Ayers et al, 2004; Cleator and Ashworth, 2004;
Chang et al, 2005a; Hannemann et al, 2005; Iwao-Koizumi et al,
2005; Modlich et al, 2005; Rouzier et al, 2005; Dressman et al, 2006;
Reis-Filho et al, 2006b). Although some of these results are
promising, issues related to the instability of mRNA, experimental
design and data analysis have led many to call into question the
validity of current approaches (Ransohoff, 2004; Brenton et al,
2005; Ioannidis, 2005; Reis-Filho et al, 2006b).
Chromosomal comparative genomic hybridisation (cCGH) has
been widely used to analyse the pattern of unbalanced genomic
aberrations in breast cancer (Roylance et al, 1999; Buerger et al,
1999a, b; Albertson, 2003; O’Connell, 2003; Reis-Filho et al, 2005a).
More recent studies have employed higher resolution array-based
CGH (aCGH) showing the enormous complexity of breast cancer
genomes. Nonetheless, these studies have consistently reported the
same regions of gain (1q, 8q, 11q, 17q, 20q) and loss (8p, 9p, 13q,
16q) (Rennstam et al, 2003; Loo et al, 2004; Naylor et al, 2005;
Nessling et al, 2005). Unbalanced chromosomal aberrations and
changes in gene copy numbers have been reported as a mechanism
for acquired drug resistance to chemotherapy in cell line studies
(Leyland-Jones et al, 1999; Yasui et al, 2004). However, no
genome-wide analysis addressing response prediction by aCGH in
breast cancer patients has been published.
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sThe primary aim of this study was to determine whether aCGH
could be used to identify unbalanced genomic changes predictive
of response to preoperative doxorubicin and cyclophosphamide
(AC) combination. We also sought to investigate the hypotheses
that resistance to chemotherapy could be driven either by selection
of chemotherapy resistant populations of neoplastic cells or by the
induction of specific genomic aberrations.
MATERIALS AND METHODS
Patients and samples
Patients were recruited and treated at the Royal Marsden
Hospital (Sutton and London, UK). Eligible patients were those
undergoing neoadjuvant adriamycin and AC chemotherapy
treatment at doses of 60 and 600mgm
 2, respectively,
three weekly, for a clinically measurable breast cancer. Approval
by the Royal Marsden Hospital Clinical Research and Ethics
committees was granted and written consent was obtained in
all cases. Patients were offered neoadjuvant treatment for one of
several standard indications including locally advanced or
inflammatory breast cancer, high tumour to breast size ratio and
tumours located close to the nipple. The majority of the patients
were from a previously published study on RNA expression
profiling (Cleator et al, 2006).
Diagnosis was confirmed on core-cut biopsies subjected to
routine histological analysis. Patients who demonstrated at least a
partial clinical response received six cycles of treatment before
local treatment. Patients with no or only marginal response after
three or four cycles, proceeded directly to local treatment or were
commenced on alternative systemic treatment (docetaxel).
Clinical size of tumour was recorded as the largest diameter and
a diameter perpendicular to this. This was recorded before
commencement and at completion of treatment. Clinical response
was categorised as follows: no palpable abnormality after
treatment, complete clinical response (cCR); 450% reduction in
the product of the bidimensional measurements, partial response
(PR); o50% reduction in the product of bidimensional measure-
ments was recorded as no change (NC); residual ill-defined
thickening after a good response, minimal residual disease (MRD)
(Cleator et al, 2006). No patients in the study demonstrated
progressive disease, an increase of more than 25% in the product
of bidimensional measurements. Those cases in which there was
no residual invasive carcinoma at surgery were classified as a
complete pathological response (pCR). Good responders were
defined as pCR, cCR, MRD; poor responders were defined as PR or
NC. Eight patients undergoing a complete clinical and radiological
(on ultrasound) response received radiation only as local
treatment. Therefore some of the cCRs may represent undocu-
mented pCRs.
Research 14-gauge core biopsies were collected before commen-
cing treatment and again at 21 days after first treatment. Samples
were snap frozen in liquid nitrogen. All samples were thereafter
coded using a study number as an identifier. Frozen cores were
embedded in optimum cutting temperature embedding compound
and sectioned at  201C in a cryostat. Sections (5mm thickness)
were taken for hematoxylin and eosin staining to assess
histological character superficially from the core as soon as ‘full-
face’ was reached. The percentage of cells comprising invasive
malignant disease was recorded. For patients in whom multiple
biopsies were available, that with the highest invasive content was
used for microarray analysis. Samples with less than 20% invasive
cancer content were excluded from the study. Eight micrometer
thick, nuclear fast red-stained representative frozen sections
from 44 patients with primary breast cancer obtained before
a neoadjuvant combination of AC were microdissected. In 22
patients consent for a second research core needle biopsy was
granted and the procedure was technically feasible; in 17 of these,
samples obtained 3 weeks after first course of chemotherapy
(before cycle two) contained proportions of neoplastic cells
suitable for microdissection (i.e. 420% of neoplastic cells).
Twenty-one surgical formalin-fixed paraffin-embedded resection
samples taken after 4–6 cycles of AC and with sufficient amounts
of residual neoplastic cells were retrieved from the pathology files
of the Royal Marsden Hospital.
Fluorescent in situ hybridisation
Fluorescent in situ hybridisation (FISH) analysis was performed
on representative 4-mm sections using PathVysion HER-2 DNA
probe mixture containing a HER-2 DNA probe (190kb Spectrum
Orange directly labelled DNA probe) and the CEP 17 DNA probe
(5.4kb Spectrum Green directly labelled fluorescent DNA probe
specific for the chromosome 17 a-satellite DNA sequence) as
described previously (Dowsett et al, 2003). A total of 60 cells were
scored for red and green signals for each section and results were
expressed as a ratio of red to green signals, with a ratio X2.0 being
considered amplified (Dowsett et al, 2003).
Microdissection and DNA extraction
Frozen and formalin-fixed samples were subjected to aCGH
analysis after microdissection of neoplastic cells with a sterile
needle under a stereomicroscope (Olympus SZ61) from one to
three consecutive 8mm nuclear fast red-stained sections
(median¼1). Estimated purity of tumour cells ranged from 75
to 100% (median¼90%) (Supplementary Figure 1). DNA was
extracted according to standard methods (Reis-Filho et al, 2005b).
The DNA yield and purity was assessed by spectrophotometry and
the DNA quality (DNA fragment size range) by agarose gel
electrophoresis as described previously (Reis-Filho et al, 2005b).
Microarray-based comparative genomic hybridisation
Microarray-based CGH was performed with in-house produced
microarrays containing B5.8K bacterial artificial chromosome
(BAC) clones, spaced out throughout the genome in B0.9Mb
intervals. The Breakthrough Breast Cancer Research Centre CGH
microarray is composed of the same BAC clones as described by
Reis-Filho et al (2005b).
Mapping of the BAC clones was retrieved from public sources
and positioned according to the May 2004 build of the human
genome sequence (hg17). When genomic positioning was dubious
or conflicting, BAC end pair sequencing and FISH mapping
was performed. Clones that either (i) showed poor quality end
sequences or (ii) hybridised to multiple chromosomal locations or
to a cytogenetic location inconsistent with their position in the
sequence assembly were excluded from analysis. Bacterial artificial
chromosome clones were spotted in triplicate onto Corning
GAPSII-coated glass slides (Corning, NY, USA). Labelling of
250ng of non-amplified DNA obtained from microdissected frozen
sections or 1000ng of DNA retrieved from microdissected
formalin-fixed paraffin-embedded tissue sections, hybridisation
and washes were carried out essentially as described previously
(Reis-Filho et al, 2005b, 2006a; Natrajan et al, 2006).
Arrays were scanned with a GenePix 4000A scanner (Axon
Instruments Inc., Union City, CA, USA); fluorescence data were
processed with GenePix 4.1 image analysis software (Axon
Instruments Inc.) as described previously (Reis-Filho et al,
2005b, 2006a; Natrajan et al, 2006).
Data analysis
The log2 ratios were normalised for spatial and intensity-
dependent biases using a two-dimensional Loess local regression.
Experiment replicates (‘dye-swaps’) were collated, BAC clone
aCGH of breast cancer
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cibility between replicates (s.d. 40.2). Samples with 470%
missing/poor values were excluded, as were clones with missing/
poor values in 470% samples. Missing data were imputed by
k-nearest neighbours (Troyanskaya et al, 2001) and clones with
no mapping information (May 2004 build of the human genome
sequence, hg17) were excluded. A total of 5001 different BAC
clones were used in the final analysis.
Statistical analysis
All data transformation and statistical analysis were carried out
in R 2.0.1 (http://www.r-project.org/), BioConductor 1.5 (http://
www.bioconductor.org/), making extensive use of modified ver-
sions of the package aCGH in particular (Paris et al, 2004; Natrajan
et al, 2006) and S-Plus (version 6.2.1). The log2 ratio of each BAC
clone in each tumour sample was centred by the median of each
case. Thresholds for determining copy number gains and losses
were determined as exceeding 73.0 s.d. of the mean of these
control experiments (log2 ratio of 71). For identification of
DNA copy number alterations, data were smoothed using a
local polynomial adaptive weights smoothing procedure for
regression problems with additive errors (Hupe et al, 2004;
Natrajan et al, 2006).
Associations between genomic loci were assessed by calculating
Pearson’s correlations between thresholded values for each clone,
assigned as 1, 0 or  1 for gain, NC, or loss in copy number.
Thresholded data for each clone were also used for categorical
analysis using a Fisher’s exact test adjusted for multiple-testing
with a correction for multiple testing using the step-down
permutation procedure maxT, providing strong control of the
family-wise type I error rate.
RESULTS
Patient, tumour and biopsy characteristics
A total of 44 patients were included in the study. Patient and
tumour characteristics are summarised in Table 1 according to
clinical response. Median tumour diameter was 4cm (range 2–10).
Two patients had inflammatory breast cancer (T4d). Median
follow-up was 24 months (range, 9–38 months).
Of the 44 patients, 24 (55%) demonstrated a ‘good’ and 20 (45%)
a ‘poor’ clinical response. Four patients (9%) were documented as
undergoing a pathological Complete Response (pCR), 17 (37%)
underwent a cCR and three (7%) had ill-defined thickening
(MRD) at end of treatment; eight (19%) had a PR and 12 (28%)
showed NC.
Validation of aCGH method
DNA was extracted from 61 frozen samples. The median DNA
yield obtained per sample was 660ng (range 152–3188ng). Owing
to constraints in amount of tumour material available from frozen
core biopsies after manual dissection, we assessed the reproduci-
bility and quality of profiles obtained with 250, 500 and 1000ng of
tumour DNA. All DNA concentrations showed optimal results,
with the Pearson’s coefficient of correlation ranging from 0.93 to
0.96 (data not shown). Biological replicates of aCGH experiments
also demonstrated high reproducibility: two independent research
core biopsies were obtained before neoadjuvant chemotherapy for
five patients. DNA extraction and CGH arrays were performed
separately for these paired samples. For each of the matched pairs,
the Pearson’s correlation coefficient ranged from 0.64 to 0.86
(mean 0.78, data not shown). In six cases, HER2 amplification
was defined by aCGH. Fluorescent in situ hybridisation analysis
confirmed the results in all cases, providing further evidence to
support the validity of the aCGH analysis methods employed in
this study (data not shown).
For six cases, high-resolution cCGH was performed and the
genetic profiles compared with those obtained with aCGH.
Correlation was good-to-excellent, with correlations for low-level
gains and deletions 420Mb and any amplification ranging from
60 to 87.5% (median¼79.5%, mean¼77.8%, data not shown).
However, aCGH was more sensitive in detecting small losses and
low-level gains than HR-CGH.
Genomic alterations in 44 pre-chemotherapy breast cancer
samples
To identify genomic regions harbouring recurrent unbalanced
genomic changes, we plotted the frequency of tumours showing
gain or loss for each BAC across the genome (Figure 1A). The most
frequent (430%) genomic changes (Table 2) comprised gains of
1q (66%), 5p (32%), 8q (70%), 16p (36%) and 20q (41%) with the
smallest regions of genomic gain on 1q31.1–1q31.2 and 1q22–
1q25.3, 5p15.31–5p15.33, 8q23.1–8q25.1, 16p11.2–16p12.2 and
Table 1 Patient and tumour characteristics
Patients
Responders
(n¼24)
Non-responders
(n¼20) P-value
Patient age
p40 5 2 0.57*
440 19 18
Menopausal status
Post 12 6 0.22*
Pre 12 13
1 unavailable
Tumour size
T2 15 10 0.40*
T3/T4 9 10
Nodal status
N0 15 14 0.60*
N1/N2/N3 9 6
HER2 – IHC
Negative 17 19 0.03*
Positive 7 1
HER2 – FISH
Negative 19 18 0.28*
Positive 5 1
1 unavailable
Lympho-vascular invasion
Absent 19 10 0.04*
Present 5 10
Histological type
Invasive ductal 19 18 0.39**
Lobular 5 2
Medullary 1 0
Metaplastic 0 1
Histological grade
I0 0
II 8 10 0.26**
III 16 10
Oestrogen receptor
Negative 8 7 0.6*
Positive 16 13
FISH¼fluorescent in situ hybridisation. *: Fisher’s exact test; **: w
2 test.
aCGH of breast cancer
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s20q13.13–20q13.33, respectively. Losses were observed on 4q
(39%), 8p (50%), 9p (36%), 11q (32%), 13q (36%), 16q (52%) 17p
(50%) and 18q (39%) with the smallest regions of deletion on
4q32.3–4q33, 8p21.1–p23.3, 9p22.2–9p24.3, 11q23.1–11q25,
13q14.11–13q14.3, 16q23.1–q24.3, 17p12–17p 13.3 and 18q22.1–
q23. In addition to the large regional alterations, the resolution of
the BAC array allowed us to map smaller regions of gain or loss.
Bacterial artificial chromosome clones gained or deleted in 430%
of the tumours are described in Supplementary Tables 1 and 2,
respectively.
Comparison of genomic alterations in different
phenotypes of breast cancer
On the basis of three distinguishing phenotypic characteristics
(ER, HER2 and histological type), we characterised genetic
alterations that might be associated with subtypes of breast cancer
on the 44 pretreatment biopsies. Oestrogen receptor (ER)-negative
tumours (N¼15) were characterised by significantly more
chromosomal changes than ER-positive tumours (Table 3 and
Supplementary Figure 2). Subgroup analysis showed that the
Pre-chemotherapy samples (n=44)
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Figure 1 Frequency of copy number changes in 44 invasive breast carcinomas. (A) Overall frequency of DNA copy number alterations found in 44
invasive breast carcinomas as defined by aCGH. The proportion of tumours in which each clone is gained (green bars) or lost (red bars) is plotted (y axis) for
each BAC clone according to genomic location (x axis). Vertical dotted lines represent chromosome centromeres. (B) – Pearson’s correlation matrix of all
thresholded aCGH data for 29 ER-positive, invasive breast carcinomas. Strong positive correlations are plotted as dark red, strong negative correlations as
dark blue. Note the associations between chromosomes 1p/8p, 1p/12q, 4q/8p, 7p/22, 8q/12q and 11q/12q. Bacterial artificial chromosome clones are
plotted in genome order. (C) Pearson’s correlation matrix of all thresholded aCGH data for 15 ER-negative, invasive breast carcinomas. Strong direct
plotted as dark red, strong negative correlations as dark blue. Note the associations between chromosomes 1p and 7q, 16p and 17q, and strong inverse
correlations between 1q and 14q, 2q and 9q, 4q and 15q, 6q and 11q, 7p and 11q, 7p and 12q, 9p and 16p, and 13q and 15q. Bacterial artificial chromosome
clones are plotted in genome order.
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with ER negativity: gains on 1p, 2p, 2q, 6q, 7q, 9p, 11q and 19q
with large regions on 1p31–1p34.2, 7q32–7q36 and losses on 4p,
4q, 5p, 5q, 12q and 17q as well as large regions such as the whole
long arm of chromosome 5 and whole chromosome 4.
Pearson’s correlation analysis of the subset of ER-positive
tumours (n¼29) revealed chromosomal alterations that coexist in
this group of tumours. The heat map in Figure 1B shows regions of
positive (change in same direction: red) and negative (change in
opposite direction: blue) correlations. Relatively large regions of
correlation were seen between changes in copy number of BACs on
chromosome 1p and 8p (Po0.01), 3p and 4p (Po0.001), 4q and 8q
(Po0.01) and 8q and 12q (Po0.01) were observed, as were strong
inverse correlations between 1p and 12q (Po0.0005), 7p and 22
(Po0.001) and 11q and 12q (Po0.001) (Figure 1B). Pearson’s
correlation matrix of ER-negative tumours revealed strong direct
associations between 1p and 7q (Po0.001), 16p and 17q
(Po0.001), and strong inverse correlations between 1q and 14q
(Po0.005), 2q and 9q (Po0.001), 4q and 15q (Po0.001), 6q and
11q (Po0.001), 7p and 11q (Po0.001), 7p and 12q (Po0.01), 9p
and 16p (Po0.001) and 13q and 15q (Po0.005) (Figure 1C).
Comparing invasive lobular carcinomas (n¼7) with non-lobular
cases (37 cases), 16q loss (from 16q12.1 to 16q24.3) was significantly
associated with lobular phenotype (unadjusted Fisher’s exact test
o0.01) (Supplementary Table 3 and Supplementary Figure 3). This
region contains a number of cadherin genes (CDH1, CDH3, CDH5,
CDH 8, CDH 11). Gain of 8q21.11–q24.23 was significantly
associated with the ductal phenotype (Supplementary Table 3 and
Supplementary Figure 3).
Comparison between the six cases with HER2 amplification on
17q11.2 with the 38 HER2-negative cases revealed more frequent
gains of 6p25.2–p24.2, 17q12 and Xp22.33–p11.36, and loss of
18p11.31 (Supplementary Table 3 and Supplementary Figure 4).
On the other hand, loss of 16q23.3–q24.1 was more frequently
observed in HER2 – tumours. This would be expected given that
all HER2þcases were of histological grade III and loss of 16q is
significantly less frequently found in this group of tumours (Reis-
Filho et al, 2005a; Simpson et al, 2005).
Prediction of tumour response
Comparison of the molecular genetic profiles of objective clinical
responders (complete and partial clinical responders, N¼24) with
those of non-responders revealed loss of a 13.3Mb region on
13q31.1–13q32.2 to be the only significant difference (Figure 2).
This region includes the genes SLITRK6, SLITRK5, GPC5, GPC6,
DCT, TGDS, SOX21, ABCC4, CLDN10, DZIP1, DNAJC3, UGCGL2,
HS6ST3, HSP90AB6P, OXGR1, MBNL2 and RAP2A. In addition,
this region also encompasses the micro RNA cluster miR-17-92,
which is reported to induce tumour cell growth and to be
overexpressed and sometimes amplified in aggressive forms of
lung cancer (Hayashita et al, 2005).
Comparison of pre-chemotherapy samples to D21 samples,
before cycle two of AC
Unsupervised hierarchical clustering analysis based upon genetic
alterations on all chromosomes showed that all pre- and D21 post-
biopsies clustered together (N¼17 cases) (Figure 3A). There were
no significant differences in the profiles between poor (10 cases)
and good responders (seven cases) (P¼0.95, Kolmogorov–
Smirnov test). The comparison of the pattern and frequency of
unbalanced genomic changes detected by aCGH analysis in
matched pretreatment and D21 biopsies revealed no significant
differences (multi-Fisher’s exact test, data not shown).
Comparison of pre-chemotherapy samples to surgical
samples, after 4–6 cycles of AC
Twenty-one surgical samples out of 44 cases were available (48%).
All but three segregated with the respective pre-chemotherapy
sample by unsupervised hierarchical clustering (Figure 3B). For 12
cases, pre-, D21 and at surgery samples were available. Unsuper-
vised hierarchical clustering analysis based upon genetic altera-
tions on all chromosomes was performed. All 12 ‘triplicates’
clustered together.
Comparison between the genomic profiles obtained with DNA
extracted from matched frozen and formalin-fixed pretreatment
core biopsies were performed (n¼2). The profiles showed a good
concordance (r
240.8). Subsequently, a comparison of the aCGH
profiles of 21-matched pretreatment core biopsies and the
respective excision specimens obtained after 4 months of
neoadjuvant chemotherapy revealed the presence of gains of
4q13.1 (9/21, 43%), 11p15.2–p15.5 (14/21, 66%), 12q13.3 (14/21,
66%), 18p11.21 (12/21, 52%) and 19q13.2 (12/21 52%) in the
excision specimens (Figure 4 and Supplementary Table 4). After
FDR adjustment, only the gain on 11p15.2–p15.5 retained its
statistical significance. Although we cannot completely rule out
that this change could result from the comparison between DNA
Table 2 Recurrent gains and losses of genomic material in 430% of the
samples
Gain region
Start
(Mb)
End
(Mb) Loss region
Start
(Mb)
End
(Mb)
1p12–qtel 119.8 245.2 1p31.1 75.3 78.3
2p25.3–p25.1 0.1 8.9 1p31.1–p21.3 79.2 97.8
3q26.1–q29 163.8 198.3 1p32.1–p31.1 58.7 69.1
5p13.3–p12 31.9 44.9 1p36.33–p34.2 1 42.9
5p15.33–p14.3 0.4 20.6 3p24.3–p13 20.2 74.2
6p12.3–p12.1 49.6 53.5 4p15.31–p15.2 18 26.6
6p24.3–p22.1 7.3 31.2 4p16.1–p15.33 7.2 15.4
7q34–q35 142.2 144.8 4q21.23–q35.2 85.1 190.9
8p12 36.8 37.9 5q11.2–q13.2 54.7 71
8p12–qtel 38.3 144.9 5q13.2–q35.1 72.4 170.2
10p15.3 0.1 1.2 6q13–q16.2 74.5 99.7
10p15.3–p12.1 2.2 27.8 6q21–23.2 105.8 131.9
12p11.22–q11 29.5 36.9 6q25.1–qtel 151.7 170.4
12p12.1–p11.22 21.3 29.3 8p23.3–p12 0.3 36.7
12p13.2–p12.1 9.8 21.3 9p24.3–q21.1 0.1 68.5
12p13.33–p13.31 0.1 8.1 9q22.2–q31.1 87.4 99.8
12q13.3–q14.1 56.5 58.3 10p15.3 0.9 1.2
12q15–q21.1 67.6 71.2 10q25.3–qtel 118.4 135.1
12q24.3–q25.1 67.1 71.8 11p15.2 14.8 15.2
12q25.1–qtel 73 78.2 11q14.2–q14.3 86.4 88.9
15q26.2–q26.3 96.3 97.7 11q14.3–qtel 91.9 133.7
16p13.3–p11.2 0.9 32.9 12q22–q24.23 94.9 118.2
20p11.21 23.3 26.2 12q24.31–qtel 121.6 132.2
20q11.21–q13.33 30 62.4 13q12.11–q31.1 18.3 85.2
13q33.1–qtel 100.2 114.1
14q23.3–q24.3 63.1 76.9
14q31.1–q32.11 79.5 87.9
14q32.12 90.8 91.4
15q11.2–q14 20.5 33.3
15q14 33.4 37.5
15q21.3–q24.3 55.1 75.5
15q25.1 78.6 79.3
15q25.2–q26.1 81.6 89.6
15q26.1–q26.2 91.4 94.6
15q26.3–qtel 97.9 99.9
16q12.1–qtel 46.4 88.5
17p13.3–q11.2 1.1 34.1
18p11.31–p11.23 6.1 7.6
18q11.2–q12.1 20.6 25.6
18q12.3–qtel 40.6 75
19q13.31–q13.32 48.9 50.1
22q11.21–q13.33 17.3 49.2
23q22.1–q28 98.6 146.7
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telomeric region encompasses interesting oncogene candidates,
such as H-RAS, a bona fide oncogene, and IGF2, which has been
reported to show loss of imprinting in up to 30–60% of breast
cancers (McCann et al, 1996; Wu et al, 1997). In the pre-
chemotherapy samples, gain on 11p15.2–p15.5 was observed in
five out of 10 good responders and in two out of 11 poor
responders (not significant, Fisher’s exact test).
DISCUSSION
In the present study, the frequency and pattern of unbalanced
genomic aberrations were similar to those described in previous
studies where genome-wide changes were analysed by means of
chromosomal CGH (Tirkkonen et al, 1998; Buerger et al, 1999a,b;
Roylance et al, 1999; Seute et al, 2001; Rennstam et al, 2003) and
aCGH (Callagy et al, 2005; Naylor et al, 2005; Nessling et al, 2005).
Table 3 Copy number changes significantly more prevalent in ER-negative compared to ER-positive tumours
ER negative vs
ER positive Start End Genes (regions o15Mb)
Gain
1p21.1–p13.1 102.8 117.2
1p31.3–p21.3 63.2 97.8
1p34.3–p32.3 39 55.1
2p11.2–q11.2 85.6 97.9
2p16.1–p14 58.3 65.4 BCL11A, PAPOLG, REL, PEX13, AHSA2, USP34, XPO1, CCT4, COMMD1, B3GNT1, TMEM17, EHBP1, OTX1, MDH1, UGP2,
VPS54, PELI1, AFTIN, SERTAD2, SLC1A4, CEP68, RAB1A, ACTR2, SPRED2
2p25.3–p25.1 0.4 12
2q24.1 158 159.7 ACVR1C, ACVR1, UPP2, PKP4, TANC1
6q23.2 131.3 134.9 AKAP7, ARG1, CRSP3, ENPP3, OR2A4, CTAGE4, ENPP1, CTGF, MOXD1, STX7, TAAR9, TAAR8, TAAR6, TAAR5, TAAR2, TAAR1,
VNN1, VNN3, VNN2, RPS12, EYA4, TCF21, TBPL1, SLC2A12, SGK
7q32.3–q33 130.9 134 PLXNA4B, CHCHD3, EXOC4, SLC35B4, AKR1B1, AKR1B10, BPGM
7q34–qtel 141.3 158
8q11.21 48.9 51.4 MCM4, UBE2V2, EFCAB1, SNAI2
9p24.1–p22.2 5.1 18
11q24.1-qtel 121 133.7
12q13.13 49.8 52.8 POU6F1, DAZAP2, BIN2, ELA1, GALNT6, SLC4A8, SCN8A, ACVR1B, ANKRD33, ACVRL1, GRASP, NR4A1, KRT7, KRTHB1,
KRTHB6, KRTHB3, KRTHB5, KRTHB4, KRTHB2, KRT6B, KRT6E, KRT6A, KRT5, KRT2A, KRT1, KRT1B, K22O, KRT3, KRT4, KRT8,
KRT18, EIF4B, TENC1, SPRYD3, IGFBP6, SOAT2, CSAD, ZNF740, ITGB7, RARG, MFSD5, ESPL1, PFDN5, MYG1, AAAS, SP7, SP1,
AMHR2, PCBP2, MAP3K12, TARBP2, NPFF, ATF7, ATP5G2, CALCOCO1, HOXC13, HOXC12, HOXC11, HOXC10, HOXC9,
HOXC8, HOXC6, HOXC5, HOXC4
19p13.11 19.2 21.3 TM6SF2, GATAD2A, SF4, TSSK6, NDUFA13, CILP2, PBX4, EDG4, GMIP, ATP13A1, ZNF101, ZNF14, ZNF506, ZNF56, ZNF93,
ZNF682, ZNF90, ENH5, ZNF486, ENT1, ZNF626, ZNF85, ZNF430, ZNF714, ZNF431, ZNF708
19q13.2 44.1 44.9 MRPS12, FBXO17, FBXO27, PAK4, IL28B, IL28A, IL29, LRFN1, GMFG, SAMD4B, PAF1, IXL, ZFP36, PLEKHG2, RPS16, SUPT5H,
TIMM50, DLL3, SELV, LGALS13, LGALS14
19q13.2–q13.31 45.2 48.8 MAP3K10, TTC9B, AKT2, PLD3, HIPK4, PRX, SERTAD1, SERTAD3, BLVRB, SPTBN4, SHKBP1, LTBP4, NUMBL, ADCK4, ITPKC,
SNRPA, RAB4B, EGLN2, CYP2A7, CYP2B, CYP2B6, CYP2G1P, CYP2A13, CYP2F1, CYP2S1, AXL, HNRPUL1, TGFB1, BCKDHA,
EXOSC5, CEACAM21, CEACAM4, CEACAM7, CEACAM5, CEACAM6, CEACAM3, LYPD4, DMRTC2, RPS19, CD79A, ARHGEF1,
RABAC1, ATP1A3, GRIK5, ZNF574, POU2F2, DEDD2, ZNF526, GSK3A, ERF, CIC, PAFAH1B3, EGFL4, CNFN, LIPE, CEACAM1,
CEACAM8, PSG3, PSG8, PSG1, PSG6, PSG4, PSG11, PSG5, PSG9, TEX101, LYPD3, PHLDB3, ETHE1, ZNF575, XRCC1, IRGQ,
ZNF576
Loss
4p15.32–p15.2 16.9 26.6 QDPR, LAP3, MED28, CND3, SLIT2, KCNIP4, GPR125, GBA3, PPARGC1A, DHX15, SOD3, LGI2, PI4K2B, ZCCHC4, ANAPC4,
SLC34A2, Q9BRT5, RBPSUH, CCKAR, TBC1D19, STIM2
4p15.33–p15.32 8.8 15.4 DB131, GAK19, ENK19, DRD5, SLC2A9, WDR1, HS3ST1, HSP90AB2P, RAB28, BAPX1, FAM44A, Q6PID2, CPEB2, C1QTNF7,
FBXL5, BST1, CD38
4p16.3–16.1 3.5 8.6
4q24–q34.3 106.7 178.4
4q35.1–q35.2 186.4 188.8 LRP2BP, ANKRD37, PDLIM3, SORBS2, TLR3, CYP4V2, KLKB1, F11, MTNR1A, FAT
5p15.33 2.8 5 IRX1
5q11.1–q13.2 50.1 71
5q13.2–q14.3 72.4 85.5 BTF3, ANKRA2, UTP15, ENC1, HEXB, GFM2, TIP1, GCNT4, ANKRD31, HMGCR, COL4A3BP, POLK, SV2C, IQGAP2, F2RL2, F2R,
F2RL1, S100Z, CRHBP, AGGF1, ZBED3, PDE8B, WDR41, OTP, TBCA, AP3B1, SCAMP1, LHFPL2, ARSB, DMGDH, BHMT2,
BHMT, HOMER1, PAPD4, CMYA5, THBS4, SERINC5, ZFYVE16, MSH3, RASGRF2, CKMT2, ZCCHC9, ACOT12, SSBP2, ATG10,
RPS23, XRCC4, CSPG2, HAPLN1, EDIL3
5q15 92.7 96.1 NR2F1, ANKRD32, MCTP1, FAM81B, ARSK, GPR150, SPATA9, RHOBTB3, GLRX, ELL2, PCSK1, CAST
5q22.1–q23.3 110.9 131.6
5q23.3–q33.1 132.2 148.5
5q33.1–q35.2 150.2 175.5
12q13.11 44.7 44.9 SLC38A1
12q13.12–q13.13 46.3 50.6 PP11, RAPGEF3, HDAC7A, VDR, TMEM106C, COL2A1, SENP1, PFKM, ASB8, OR10AD1, H1FNT, ZNF641, ANP32D, OR8S1,
LALBA, CCNT1, ADCY6, CACNB3, DDX23, RND1, CCDC65, FKBP11, ARF3, WNT10B, WNT1, DDN, PRKAG1, MLL2, RHEBL1,
DHH, LMBR1L, TBAK, TBA3, TUBA6, PRPH, TROAP, C1QL4, SPATS2, KCNH3, MCRS1, PRPF40B, FMNL3, TEGT, FAIM2, AQP2,
AQP5, AQP6, RACGAP1, SMARCD1, GPD1, LASS5, LIMA1, LARP4, DIP2B, ATF1, TMPRSS12, METTL7A, SLC11A2, LETMD1,
TAI12, TFCP2, POU6F1, DAZAP2, BIN2, ELA1, GALNT6, SLC4A8, SCN8A, ACVR1B, ANKRD33, ACVRL1
13q14.2 45.7 47.8 LRCH1, ESD, HTR2A, SUCLA2, NUDT15, MED4, ITM2B, RB1
13q21.1–q21.31 57.1 60.8 PCDH17, DIAPH3, TDRD3
17p11.2–q11.2 21.2 30.3 KCNJ12, FAM27L
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sRecurrent gains on chromosome 1q, 8q, 11q, 17q and 20q and
losses on 6q, 8p, 9p, 13q and 16q were the most prevalent changes.
In addition, we confirmed the association between ER positivity
and gain of 1q coupled with loss of 16q (Farabegoli et al, 2004;
Reis-Filho et al, 2005a; Simpson et al, 2005) and the more
prevalent deletions of 4p16 and 4p15, 5q and 17p11.2 in ER-
negative tumours (Loo et al, 2004). In contrast to previous studies
(Loo et al, 2004), gains of 8q24.1 (MYC) and 17q12 (HER2) were
not significantly more frequent in ER-positive tumours. This is
expected, given that only breast carcinomas of histological grades 2
and 3 were present in the population and gains of 8q are rather
frequent in grade 2 and 3 breast cancers (Buerger et al, 1999a,b;
Roylance et al, 1999).
The comparison between the genomic profiles obtained for
ductal and lobular carcinomas were also in agreement with
previous studies (Buerger et al, 1999b; Shelley Hwang et al, 2004;
Reis-Filho et al, 2005a; Simpson et al, 2005; Stange et al, 2006):
gain of 1q and deletions of 16q were the most prevalent changes in
lobular carcinomas, whereas gain of 8q was significantly more
frequent in grade 2 and 3 ductal carcinomas. However, we could
define the smallest region of overlap of the deletions of 16q, which
mapped to 16q21–q22.1 and encompassed the region of the
cadherin gene cluster, and the gain of 8q, which encompassed two
regions 8q13.2–q21.13 and 8q21.3–qtel (Supplementary Table 3).
The most significant gain comparing ductal carcinoma with
lobular carcinomas mapped to 8q24.11 (117.8–118.0Mb), which
encompasses RAD21 and eucaryotic translation initiation factor 3,
subunit 3 gamma (EIF3S3). RAD21 is believed to function in sister
chromatid alignment as part of the cohesin complex and also in
double-strand break repair and influences cellular proliferation
(Atienza et al, 2005), whereas EIF3S3 is reported to be amplified
and overexpressed in up to 20% of breast carcinomas (Nupponen
et al, 1999). Our observations are consistent with previous studies
on breast cancer, confirming the robustness of our aCGH protocol,
the validity of our analysis method and the likelihood that we have
a representative set of tumours.
Several attempts have been made to predict clinical or
pathological response to neoadjuvant chemotherapy in breast
cancer using gene expression arrays. Gene ‘signatures’ or
predictors have been devised for several chemotherapy regimens,
including paclitaxel followed by fluorouracil, AC, AC/doxorubicin-
docetaxel and taxane only chemotherapy (Chang et al, 2003, 2005b;
Ayers et al, 2004; Hannemann et al, 2005; Cleator et al, 2006).
Although these results are promising, the exceedingly small sample
size and limitations with the current technology and analysis
methods have so far precluded definitive conclusions (Brenton
et al, 2005; Reis-Filho et al, 2006b).
We have recently reported a similar expression profiling study
(Cleator et al, 2006) that included the 44 patients studied here plus
a small number of others for whom pretreatment tissue for DNA
analysis was not available. Neither unsupervised nor supervised
methods could separate the responders from non-responders.
In the current study, using the same cohort of patients, which
included 24 good clinical responders, aCGH analysis revealed a
deletion of a large region from 13q31.1 to 13q34 as the only
significant copy number change associated with response to
chemotherapy. Although this statistical association lost its
significance after correction for multiple comparisons, the
correction method, which we adopted may be too conservative,
given that unbalanced chromosomal aberrations usually encom-
pass more than one BAC clone. One of the genes deleted in this
region is a subtype of heat-shock protein 90, HSP90AB6. HSP 90 is
a molecular chaperone whose association is required for stability
and function of multiple signalling proteins that promote cancer
cell growth and/or survival (Chen et al, 2005). Further studies with
a larger sample size focusing on this particular region are
warranted. We cannot exclude the possibility that analysis similar
to ours of a larger series of samples might identify other DNA
aberrations of importance for response to AC chemotherapy. It is
however likely that if these were present in a large proportion of
the population they would have been uncovered by the present
analysis.
Sequential sampling of tumour during neoadjuvant treatment
can be used to detect gene expression modification induced by
therapy as we have demonstrated with endocrine therapy (Mackay
et al, 2005). This was demonstrated for chemotherapy by
Hannemann et al (2005), who observed that tumours that
responded to neoadjuvant chemotherapy showed dramatic
123 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 19 20 2122 XY
123 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 19 20 2122 XY
123 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 19 20 2122 XY
–1.0
–0.2
0.6
–1.0
–0.2
0.6
–10
–4
2
6
Non-responders
Non-responders vs responders
Responders
F
r
a
c
t
i
o
n
 
g
a
i
n
e
d
 
o
r
 
l
o
s
t
F
r
a
c
t
i
o
n
 
g
a
i
n
e
d
 
o
r
 
l
o
s
t
F
i
s
h
e
r
 
P
-
v
a
l
u
e
Figure 2 Categorical analysis of copy number gains and losses between non-responders (N¼20) and responders (N¼24). Fisher’s exact tests are
carried out on the segmented values for each clone, and those with a P-value of less than 0.01 are plotted (inverse log10, y axis) according to genomic
location (x axis).
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schanges in their expression profiles when compared to the changes
observed in non-responders (Hannemann et al, 2005). On the
other hand, a comparison between the transcriptomic profiles of
tumours subjected to taxane-based neoadjuvant chemotherapy
before and 3 months after treatment revealed strikingly different
patterns, independent of initial sensitivity or resistance (Chang
et al, 2005b).
Cell line studies have demonstrated that changes in gene
copy numbers may lead to acquired resistance to chemotherapy
(Leyland-Jones et al, 1999; Shimizu et al, 2002; Yasui et al,
2004). Specific gains of genetic material mapping to multi-drug
resistance (MDR) gene MDR1 locus have been reported in
drug resistant cell lines (Shimizu et al, 2002; Kuwano et al,
2003). Recurring amplicon 7q11.2–q21 identified by CGH in
doxorubicin-resistant hepatocellular carcinoma cell lines coin-
cided with the localisation of MDR1 (Pang et al, 2005). Induction
of DNA damage response genes such as p21 were obtained
by doxorubicin in breast cancer cell lines (Troester et al,
2004). Both chromosome 7 alterations and several cytogenetic
changes involving the 7q21 locus are associated with the
development of MDR in sarcoma cells (Chen et al, 2002). Analysis
of genomic amplifications and deletions revealed specific genetic
alterations common to both intrinsic and acquired doxorubicin
resistance including ABCB1, PGY3 (ABCB4) and BAK (Turton
et al, 2001).
Most patients show some tumour shrinkage with neoadjuvant
chemotherapy and for many there may be profound loss of
malignant cells with some showing a pCR. Characterisation of the
residual cells may be expected to a better understanding of the
causes of resistance and allow the identification of the means to
overcome the resistance. Given the molecular heterogeneity
between breast carcinomas and the composition of most breast
cancers being of multiple non-modal clones, we hypothesised that
the cell loss might lead to selection of breast cancer cell lineages
that were resistant to chemotherapy by virtue of specific DNA
alterations. Few studies have previously addressed this issue. A
very small study, involving CGH of just four tumours from breast
cancer patients after neoadjuvant chemotherapy (Fazeny-Dorner
et al, 2003) showed typical DNA imbalances for ductal breast
cancer. Three patients showed involvement of several regions
bearing genes of drug resistance (MDR1, BCRP, MRP1, RFC1); the
fourth patient displayed an amplification in the region of MYC.
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aCGH of breast cancer
J-Y Pierga et al
348
British Journal of Cancer (2007) 96(2), 341–351 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sIn our study, the hierarchical clustering of sequential samples at
baseline, 3 weeks and at surgery indicated that any changes
induced in DNA profiles by therapy were modest compared with
the differences that were present between the patients. This
interpretation was supported by the observation that statistically
significant chemotherapy-driven genomic changes were not
detected within 3 weeks (i.e. after a single course of chemother-
apy). Comparison of the pretreatment and the tumour specimens
excised after 4 months of neoadjuvant chemotherapy revealed
the appearance of genomic gains on 11p15.2–p15.5. Given the
experimental design of our study, we cannot define whether these
amplifications were chemotherapy induced or were present in a
non-modal population of the primary tumour and selected by
chemotherapy, as the majority of surgical samples by definition
were obtained from poor responders (66%). Interestingly,
pathological relaxation of the imprinting pattern in this region is
reported to be found in 30–60% of breast cancers (McCann et al,
1996; Wu et al, 1997). However we did not find a correlation
between amplification on 11p15.5 and clinical response (Han et al,
2006). Furthermore, these changes on surgical samples, need to be
cautiously interpreted as surgical samples were subjected to
different fixation conditions (Devries et al, 2005). Thus in contrast
to observations with cancer cell lines, we did not find large or
frequent chemotherapy-induced acquired genomic changes. Given
that aCGH provides an average of the pattern of genomic gains and
losses in the cell population studied, chemotherapy-driven losses
or low-level gains occurring in non-modal clones are unlikely to be
detected.
In conclusion, array CGH is a powerful method for the genome-
wide detection of chromosomal imbalances and allowed us to
detect molecular genetic aberrations associated with specific breast
cancer subgroups (ductal vs lobular, ER-negative vs ER-positive
tumours). A molecular genetic profile specific of good responders
to neoadjuvant chemotherapy was not detectable in our series.
Chemotherapy-driven genomic changes were not detected follow-
ing 3 weeks of treatment and only a single change after completion
of treatment. The hypothesis of resistance to neoadjuvant
chemotherapy by the selection of non-modal cell lineages, which
differ by gene amplifications or losses is not supported by our
results.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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